Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MEXATE is an antimetabolite that inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate synthesis and interfering with DNA, RNA, and protein synthesis. It also inhibits thymidylate synthetase and has immunomodulatory and anti-inflammatory effects.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Rheumatoid arthritis (moderate to severe active disease in adults),Polyarticular juvenile idiopathic arthritis,Psoriasis (severe, recalcitrant, disabling),Neoplastic diseases: gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole; acute lymphocytic leukemia (ALL); meningeal leukemia; Burkitt lymphoma; advanced non-Hodgkin lymphomas; mycosis fungoides; advanced head and neck cancer; osteosarcoma (adjunctive treatment),Off-label: ectopic pregnancy, inflammatory bowel disease, graft-versus-host disease, sarcoidosis, systemic lupus erythematosus, vasculitis
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
10-25 mg/m2 orally or intramuscularly once weekly for rheumatoid arthritis; 50 mg/m2 intravenously once weekly for psoriasis; 30-40 mg/m2 intravenously weekly for certain cancers (dose varies by protocol).
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life is 3-10 hours for low-dose therapy (≤30 mg/m²). For high-dose therapy (>100 mg/m²), terminal half-life extends to 8-15 hours due to saturable elimination. A third, prolonged terminal phase (8-72 hours) is observed in some patients due to enterohepatic recirculation.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Methotrexate is primarily metabolized by hepatic aldehyde oxidase to 7-hydroxymethotrexate. It undergoes polyglutamation intracellularly. Less than 10% is metabolized by cytochrome P450 enzymes. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal excretion of unchanged drug is the primary route of elimination, accounting for 80-90% of the dose. Biliary/fecal excretion is minor (<10%).
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
50-60% bound, primarily to albumin.
82–88% bound to plasma proteins (primarily albumin).
0.4-0.8 L/kg (total body water). Vd increases with dose, indicating tissue distribution.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral: 30-70% (dose-dependent, saturable absorption). Intramuscular: 80-100%. Subcutaneous: approximately 100%.
Oral: 65–80% (median 73%)
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: 75% of normal dose; Child-Pugh B: 50% of normal dose; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
For leukemia: 20-40 mg/m2 orally or intravenously once weekly; for juvenile idiopathic arthritis: 10-15 mg/m2 orally once weekly (max 25 mg/week).
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
Start at lowest effective dose (e.g., 5-7.5 mg/week) with close monitoring of renal function, hepatic function, and hematologic parameters due to increased toxicity risk.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
Boxed Warning: Methotrexate (MEXATE) can cause severe or fatal toxicities including bone marrow suppression, hepatic fibrosis/cirrhosis, pulmonary fibrosis, renal failure, and ulcerative stomatitis. Fatalities have been reported with inadvertent daily dosing instead of weekly. For rheumatoid arthritis and psoriasis, use only in patients with severe disease. Monitor for toxicity closely. Advise patients about risks of fatal toxicity.
None
Severe hematologic toxicity (bone marrow suppression, pancytopenia), hepatotoxicity (fibrosis, cirrhosis, acute hepatitis), pulmonary toxicity (pneumonitis, fibrosis), renal toxicity, gastrointestinal toxicity (stomatitis, ulceration), neurotoxicity (leukoencephalopathy), opportunistic infections, tumor lysis syndrome, photosensitivity, and dermatologic reactions. Avoid concomitant NSAIDs, salicylates, and nephrotoxic drugs. Monitor CBC, LFTs, creatinine, and chest imaging. Use caution in elderly, debilitated, or patients with renal impairment, ascites, or pleural effusions.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to methotrexate, alcohol abuse, pre-existing liver disease (including hepatitis), renal impairment (creatinine clearance < 60 m L/min), pre-existing bone marrow suppression, immunodeficiency, active infections (e.g., tuberculosis), pregnancy, breastfeeding, lactation.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid alcohol due to increased hepatotoxicity risk. No specific food restrictions; however, maintain adequate hydration. Folate-rich foods do not interfere but supplemental folic acid may be prescribed to reduce side effects.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Category X. 1st trimester: High risk of CNS, craniofacial, and skeletal malformations. 2nd and 3rd trimesters: Fetal growth restriction, oligohydramnios, and neonatal pancytopenia.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Contraindicated. Methotrexate is excreted in human milk; M/P ratio approximately 0.08. Potential for severe neonatal toxicity.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
Not applicable; contraindicated in pregnancy. If inadvertent exposure, discontinue and refer for fetal assessment.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Mexate (methotrexate) is a folate analog antimetabolite used in high doses for malignancy and low doses for autoimmune diseases. Reserve leucovorin rescue for high-dose protocols to prevent severe myelosuppression. Monitor renal function and methotrexate levels; adjust hydration and alkalinization to prevent precipitation in renal tubules. Avoid concurrent NSAIDs and proton pump inhibitors which reduce methotrexate clearance. Screen for pregnancy before initiation. Administer weekly in low-dose regimens for rheumatoid arthritis to avoid acute toxicity.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Take exactly as prescribed—do not increase dose or frequency. Overdose can be fatal.,Avoid alcohol completely while on this medication.,Report any signs of infection, unusual bleeding, bruising, or mouth sores immediately.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not take NSAIDs or aspirin without consulting your doctor.,Stay well hydrated; drink plenty of fluids unless otherwise instructed.,Avoid live vaccines during treatment.,Keep all follow-up appointments for blood tests and monitoring.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE vs AGRYLIN, answered by our medical review team.
MEXATE is a Antineoplastic Agent that works by MEXATE is an antimetabolite that inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate synthesis and interfering with DNA, RNA, and protein synthesis. It also inhibits thymidylate synthetase and has immunomodulatory and anti-inflammatory effects.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE is: 10-25 mg/m2 orally or intramuscularly once weekly for rheumatoid arthritis; 50 mg/m2 intravenously once weekly for psoriasis; 30-40 mg/m2 intravenously weekly for certain cancers (dose varies by protocol).. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE is classified as Category C. Category X. 1st trimester: High risk of CNS, craniofacial, and skeletal malformations. 2nd and 3rd trimesters: Fetal growth restriction, oligohydramnios, and neonatal pancytopenia.. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.